Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02250547
Other study ID # RCSY01 OSCAR
Secondary ID
Status Completed
Phase N/A
First received July 10, 2013
Last updated November 10, 2017
Start date July 2012
Est. completion date September 2017

Study information

Verified date November 2017
Source LivaNova
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Evaluate the percentage of patients optimized at least once every month by the SonR automatic optimization method, until M6 follow-up, in Heart failure (HF) patients prevalently in sinus rhythm


Description:

Thanks to the SonR technology it is possible to adjust the optimal VV and AV delays over time, in a fully automatic, time saving and operator independent way. It is possible to optimize the VV and AV delays in office, during follow-up visits, but also enable the automatic optimization that weekly optimize the AV and VV delays.

For the reasons mentioned above, the sponsor expects that the SonR optimization method increases the number of patients optimized systematically at each follow-up The purpose of this study is to evaluate the percentage of patients optimized at least once every month by the SonR automatic optimization method, until M6 follow-up, in HF patients prevalently in sinus rhythm.

The primary objective will be evaluated as the percentage of patients successfully optimized every month until M6.

A patient is considered successfully optimized by the SonR during one month if at least one Atri-Ventricular (AV) or Ventricular-Ventricular (VV) optimization is completed by the SonR automatic optimization method during the month.

Patients eligible for the analysis are those with SonR automatic optimization function enabled and at least 50% of the time in sinus rhythm


Recruitment information / eligibility

Status Completed
Enrollment 278
Est. completion date September 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient eligible for implantation or implanted for less than 6 weeks (primo-implant, replacement, upgrade) with a a Paradym RF SonR CRT-D and SonRtip Atrial Lead, according to current available guidelines (RF=radio frequency)

- Patient has signed and dated informed consent (according to the laws and regulations of the country in which the observation is performed)

Exclusion Criteria:

- Persistent atrial arrhythmias

- Already included in another interventional clinical study

- Not available for routine follow-up visits

- Inability to understand the purpose of the study

- Under guardianship

- Under18 years old

- Drug addiction or abuse

- Pregnancy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Austria Allgemeines Krankenhaus Linz (AKH LINZ) Linz
France CH Sud Francilien Corbeil Essonne
France Centre Hospitalier de Haguenau Haguenau
France CH de Marne la Vallée Jossigny
France CMC du Mans - Pôle Santé Sud Le Mans
France Polyclinique du Bois Lille
France Chu Dupuytren Limoges
France CH St Philibert Lomme
France CH St Joseph et St Luc Lyon
France Polyclinique Beauregard Marseille
France Centre hospitalier Belford Montbéliard Montbéliard
France CH Poitiers Poitiers
France Hôpital Victor Provo Roubaix
Germany Evangelisches Krankenhaus Bielefeld
Germany PAP2 - Kardiologische Praxis Papenburg Papenburg
Italy Osp. S. Salvatore L'aquila
Italy S.Giovanni Bosco Napoli
Portugal Hospital Espírito Santo, E.P.E Evora
Portugal Hospital Central Faro Faro
Portugal Centro Hospitalar Lisboa Norte (CHLN) - Hospital de Santa Maria Lisboa
Spain Hospital Universitario Virgen del Rocío Sevilla

Sponsors (1)

Lead Sponsor Collaborator
LivaNova

Countries where clinical trial is conducted

Austria,  France,  Germany,  Italy,  Portugal,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary evaluate the percentage of patients optimized at least once every month by the SonR automatic optimization method, until M6 follow-up, in HF patients prevalently in sinus rhythm The primary objective will be evaluated as the percentage of patients successfully optimized every month until M6.
A patient is considered successfully optimized by the SonR during one month if at least one AV or VV optimization is completed by the SonR automatic optimization method during the month.
Patients eligible for the analysis are those with SonR automatic optimization function enabled and at least 50% of the time in sinus rhythm
6 months
Secondary Percentage of patients with SonR automatic optimization function enabled at each follow-up The number of patients with automatic SonR optimization enabled over the total number of patients at: Implantation, Baseline, M6 6M
Secondary Analyze the evolution of optimal AV and VV delays SonR optimized over time Compare the mean and the intra-patient AV and VV delays between consecutive follow-ups 6M
Secondary Report system-related complications Report system-related complications 6M